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Abstract
To assess whether NLR pyrin domain-containing protein 3 (NLRP3) inflammasome, a multi-
protein complex that mediates the activation of caspase-1 (CASP-1) and pro-inflammatory
cytokines IL-18 and IL-1β, could be involved in the chronic inflammatory state observed in
chronic kidney disease patients undergoing hemodialysis treatment (CKD-HD), we em-
ployed several biomolecular techniques including RT-PCR, western blot, FACS analysis,
confocal microscopy and microarray. Interestingly, peripheral blood mononuclear cells from
15 CKD-HD patients showed higher mRNA levels of NLRP3, CASP-1, ASC, IL-1β, IL-18
and P2X7receptor compared to 15 healthy subjects. Western blotting analysis confirmed
the above results. In particular, active forms of CASP-1, IL1-β and IL-18 resulted significant-
ly up-regulated in CKD-HD versus controls. Additionally, elevated mitochondrial ROS level,
colocalization of NLRP3/ASC/mitochondria in peripheral blood mononuclear cells from
CKD-HD patients and down-regulation of CASP-1, IL1-β and IL-18 protein levels in im-
mune-cells of CKD-HD patients stimulated with LPS/ATP in presence of mitoTEMPO, inhib-
itor of mitochondrial ROS production, suggested a possible role of this organelle in the
aforementioned CKD-associated inflammasome activation. Then, microarray analysis con-
firmed, in an independent microarray study cohort, that NLRP3 and CASP-1, along with
other inflammasome-related genes, were up-regulated in 17 CKD-HD patients and they
were able to clearly discriminate these patients from 5 healthy subjects. All together these
data showed, for the first time, that NLRP3 inflammasome was activated in uremic patients
undergoing dialysis treatment and they suggested that this unphysiological condition could
be possibly induced by mitochondrial dysfunction.
Introduction
Chronic kidney disease (CKD) is one of the leading clinical features of nephrology patients and
it represents a major and growing challenge for healthcare systems. The prevalence rate of
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CKD is increasing worldwide [1–3], primarily as a consequence of the augmented incidence of
diabetes, hypertension, and aging population [4–6].
During this condition patients experience significant and progressive biological dysfunc-
tions associated with considerable changes in energy metabolism, nitrogen balance, protein-en-
ergy malnutrition and insulin resistance and with a significant increase in the generation of
mediators of inflammation/oxidative stress [7–9].
An international consensus categorized CKD into five stages according to the glomerular
filtration rate (GFR) [10]. In the last stage of renal failure (end stage renal disease) these alter-
ations are incompatible with life and renal replacement therapies (RRT: hemodialysis, perito-
neal dialysis and renal transplantation) are required.
Hemodialysis, most employed RRT worldwide, may induce additional biochemical alter-
ations caused by the contact of blood with dialysis devices [11,12]: phagocyte cells activation
[13,14], complement activation, cytokine synthesis and release, oxidative stress [15–18].
Oxidative stress and chronic inflammation, being strongly related, contribute to long-term
complications in HD patients, such as cardiovascular disease, atherosclerosis, anemia and mal-
nutrition [19–23].
In the last years, different therapeutic interventions have been proposed to prevent or at
least control HD-related cellular/biological alterations, including the use of biocompatible
membranes able to limit the complement activation and cytokines release; the activation of
high flux dialysis or hemofiltration that would reduce the circulating levels of complement acti-
vating molecules and the accurate use of sterile water [24,25]. Moreover, the dialysis devices
and membranes (dialysis filters) have continuously modified to improve the biocompatibility
profile of the material. However, at the moment, we are still far from the development of full
biocompatible dialysis procedure.
Therefore, the comprehension of the mechanisms underlying CKD/HD-related oxidative
stress and chronic inflammation may help to achieve this objective. In this context mitochon-
dria being involved in immune response as well as in oxidative stress could have a role.
These organelles are the “powerhouse of the cell” involved in a lot of signaling pathways: ox-
idative phosphorylation system for the production of the vast majority of intracellular ATP;
calcium homeostasis [26]; heme and steroid biosynthesis [27,28] and apoptosis [29].
In addition, as recently published, mitochondria orchestrate innate immune response
[30,31] that constitutes the first line of host defense against infection or noxious insults. In
order to recognize and respond to microbial substances or molecules that arise during tissue
damage or cellular stress, the innate immune system possesses a large number of soluble (e.g.
pentraxins), membrane-bound (e.g. Toll-like receptors) and cytosolic (e.g. Nod-like receptors)
receptors known collectively as pattern recognition receptors [32].
The Nod-like receptors or nucleotide-binding domain leucine-rich repeat-containing recep-
tors (NLRs), are a family of intracellular immune receptors with more than 20 members
known in humans [33,34]. The NLR pyrin domain-containing proteins (NLRP) constitutes an
homogenous NLR subfamily [35]. Among these the most studied is NLRP3, that interacts with
apoptosis-associated speck-like protein containing a CARD domain (ASC) and with pro-
caspase-1 forming the inflammasome [24,31]. The inflammasome mediates the activation of
caspase-1, which promotes secretion of the pro-inflammatory cytokines interleukin 1β (IL-1β)
and IL-18 [36,37].
A wide array of signals (viruses, bacteria, molecules released during or indicative of tissue
injury, environmental origin irritants) [38–40], are able to activate NLRP3 inflammasome but
the exact mechanism is poorly understood. Currently, it is well accepted that two steps are re-
quired. The first, or priming signal, converges on the activation of NFkB and transcriptional
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induction of inflammasome components including NLRP3 itself and pro-IL-1β. The second, or
activating signal, is able to directly activate inflammasome assembly [41].
Although several reports have focused on inflammasome in various kidney diseases [42,43]
no report has studied its role in chronic inflammation associated with hemodialysis. Therefore
the aim of our study was to investigate the activation of NLRP3 inflammasome in peripheral
blood mononuclear cells (PBMCs) from CKD-HD patients and the possible involvement of
mitochondrial dysfunction in this process.
Methods
Patients and Controls
A total of 52 subjects [n: 32 hemodialyzed chronic kidney disease patients (CKD-HD) and n:20
healthy subjects (NORM)], after signing informed consent, were enrolled in our study.
Thirty subjects were included in the training-group (15 NORM and 15 CKD-HD) and 22 in
the microarray-group (5 NORM and 17 CKD-HD).
Since we did not obtain sufficient number of cells for all the analysis and in order to avoid
additional blood collection, western blot experiments and FACS analysis were performed in 10
NORM and 10 CKD-HD.
The main demographic and clinical features are summarized in Table 1.
To avoid confounding factors, all patients suffering from systemic autoimmune disorders,
(e.g. SLE, vasculitis) infectious diseases, diabetes, chronic lung diseases, neoplasm, or inflam-
matory diseases and patients receiving antibiotics, corticosteroids, or non-steroidal anti-
inflammatory agents were excluded. No patients had symptomatic coronary artery diseases or
a family history of premature cardiovascular diseases.
The study was carried out according to the Declaration of Helsinki and approved by Institu-
tional Ethic Review Boards of the University Hospital of Verona, Italy and University Hospital
“Policlinico di Bari”, Bari, Italy.
Table 1. Demographics and clinical characteristics of study groups.
Training-group Microarray-group
NORM CKD-HD P-value NORM CKD-HD P-value
Number 15 15 / 5 17 /
Gender (Male/Female) 4/11 7/8 n.s. 2/3 10/7 n.s.
Age (years) 48±11.27 50.61±7.24 n.s. 50.78±10.45 52.86±8.63 n.s.
Cause of CKD: GN/ADPKD/RVD/unknown / 7,2,2,4 n.s. / 7,4,1,5 n.s.
Time on dialysis (years) / 4.01±0.42 n.s. / 3.98±0.56 n.s.
BMI (kg/m2) 22.8±0.64 21.7±0.96 p<0.01 23.1±0.82 22.1±1.01 p<0.01
Systolic blood pressure (mmHg) 121±3.71 138±8.11 p<0.01 120±4.01 138±8.11 p<0.01
Diastolic blood pressure (mmHg) 75.28±4.26 89±10.93 p<0.01 74.36±5.31 88±10.86 p<0.01
Total protein (g/dl) 6.87±0.49 5.98±0.34 p<0.01 6.98±0.41 6.02±0.31 p<0.01
Albumin (g/dl) 4.1±1.56 3.74±0.48 p<0.01 4.3±0.31 3.48±0.51 p<0.01
Hs-CRP (ng/ml) 0.66±0.3 12.48±6.4 p<0.01 0.56±0.3 11.21±4.2 p<0.01
Hemoglobin (g/dl) 13.12±1.49 11.12±2.28 p<0.01 13.46±1.62 11.48±1.98 p<0.01
GN: Glomerulonephritis; ADPKD: Autosomal dominant polycystic kidney disease; RVD: Renal vascular diseases; BMI: Body mass index; CRP: C reactive
protein. Values are expressed as mean±SD. P-values calculated by T-Test.
doi:10.1371/journal.pone.0122272.t001
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Peripheral Blood Mononuclear Cells (PBMC) isolation
Fifteen ml whole blood were collected from all subjects included in the study. For CKD-HD pa-
tients the biological material was drawn before the second dialysis of the week. PBMC were iso-
lated by density separation over a Ficoll–Paque (GE healthcare, Sweden) gradient (460 g for 30
min) and washed three times with PBS pH 7.4/1 mM EDTA (Sigma, Milan, Italy). Cells were
counted, and viability was assessed by trypan blue exclusion method (>90% PBMCs were
viable).
RNA extraction and Real-Time PCR
Total RNA was isolated from PBMC by RNeasy mini kit Qiagen (QIAGEN AG, Basel, Switzer-
land) and quantified by Quant-iT RNA Assay kit with Qubit Fluorometer (Invitrogen).
Reverse transcription of RNA was performed using the High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems), following the manufacturer’s instructions. One μg of RNA
was reverse transcribed using random primer and MultiScribe Reverse Transcriptase. Real-
time PCR amplification reactions were performed in duplicate in 20 μl of final volume via
SYBR Green chemistry on ABI-Prism 7700 (Applied Biosystem). PCR protocol was performed
using QuantiTect Primer Assays (Qiagen, Basel, Switzerland) for IL-1β, ASC, CASP-1, IL-18,
NLRP3, CARD8, P2XR7 and β-actin: 50°C for 2 min, 95°C for 2 min and 40 two-step cycles:
95°C for 15 sec and 60°C for 30 sec.
Universal master mix obtained from Kapa Biosystems included all reagents. The β-actin
gene amplification was used as a reference standard to normalize the target signal. The com-
parative Ct method (ΔΔCt) was used to quantify gene expression, and the relative quantifica-
tion was calculated as 2-ΔΔCt. Amplification specificity was controlled by a melting curve
analysis and the amount of mRNA target was evaluated using the comparative Ct method.
Mitochondrial reactive oxygen species (ROS) measurement
Freshly isolated PBMC were incubated with 5 μMMitoSOX Red mitochondrial superoxide in-
dicator (Molecular Probes, Invitrogen, Carlsbad, CA), for 10 min at 37°C, in the dark, accord-
ing to manufacturer’s instructions. Autofluorescence of unstained cells were used as control for
each sample. Approximately 40,000 gated events were acquired for each sample on a FACS-
Canto (Becton Dickinson, San Jose, CA) and analyzed using FlowJo software (TreeStar, Ash-
land, OR). Dead cells and debris were excluded based upon forward scatter and side scatter
measurements. All analyses were gated on PBMC, based on morphologic identification (for-
ward scatter vs. side scatter). Percentage of Mitosox-positive cells (fluorescence signals at 580
nm) was calculated by subtracting the percentage of autofluorescence-positive cells.
Confocal microscopy
Freshly isolated PBMC from 3 NORM and 3 CKD-HD were spotted on poly-L-lysine-coated
slides and incubated with Mitotracker deep red (Molecular Probes, Invitrogen, Carlsbad, CA),
100 nM for 30 min at 37°C according to manufacturer’s instruction. The cells were washed and
fixed with 4% paraformaldehyde (PFA). PFA was quenched with 50 mMNH4Cl. Cells were
then permeabilized with PBS-0.1% Triton X-100. After blocking with 1% bovine serum albu-
min in PBS, the slides were incubated with anti-NLRP3 and anti-ASC antibodies (Abcam) for
1 hour. The slides were then extensively washed in PBS and incubated with Alexa Fluor 488
Goat Anti-Rabbit and Alexa Fluor 594 anti-mouse. Finally, nuclei were stained with DAPI.
Negative controls were performed by omitting the primary antibodies (S1 Fig.). Images were
collected using the SP5 confocal microscope from Leica Microsystems (Wetzlar, Germany).
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Cell culture
Freshly isolated PBMC from 3 randomly selected CKD-HD were cultured in RPMI 1640 medi-
um (Sigma) supplemented with 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin
(100 μg/ml) and stimulated with LPS (10 ng/ml) (Sigma) for 4 h followed by ATP (Sigma) 1
mM for 15 min. MitoTEMPO (100 μM) (Santa Cruz) was added to the medium 1 h before
LPS priming.
Western blot
Cells derived from 10 NORM and 10 CKD-HD were lysed in RIPA buffer (1 mM phenyl-
methylsulphonylfluoride, 5 mM EDTA, 1 mM sodium orthovanadate, 150 mM sodium chlo-
ride, 8 μg/ml leupeptin, 1.5% NonidetP-40, 20 mM Tris–HCl, pH 7.4). Aliquots containing
45 μg of proteins from each lysate were subjected to SDS–PAGE on a Criterion Tris-HCl
4–20% precast gels and then transferred onto PVDF membrane (Millipore). Membranes were
incubated with primary antibodies as follows: anti-cleaved-Caspase-1 (Cell Signaling), anti-
proCaspase-1 (Cell Signaling), anti-cleaved-IL1β (Cell Signaling), anti-pro-IL-1β (Santa Cruz),
anti-IL-18 (Santa Cruz), and anti-actin (Santa Cruz). Blots were subsequently incubated with
secondary antibodies HRP-labelled (Santa Cruz Biotechnology Santa Cruz, CA). Proteins were
detected by Chemiluminescence (Amersham, GE Healthcare). Images were acquired using a
scanner EPSON Perfection 2580 Photo (EPSON, Long Beach, CA, USA) and quantified by
Image J 1.34 Software (http://rsb.info.nih.gov/ij/). The intensity of bands of interest was nor-
malized to the signal intensity of the corresponding procaspase-1, pro-IL-1β, or pro-IL-18
band present on the same membrane. Actin was used as loading control.
Microarray analysis
For all 22 patients (17 CKD-HD and 5 NORM) included in the microarray-group, RNA was
processed and hybridized to GeneChip Human Genome U133A oligonucleotide microarray
(Affymetrix, Santa Clara, CA) which contains 22,283 gene probe sets, representing 12,357
human genes, plus approximately 3,800 expressed sequence tag clones (ESTs), according to
manufacturer’s instructions. We used the default settings of Affymetrix Microarray Suite soft-
ware version 5 (MAS 5.0; Affymetrix) to calculate scaled gene expression values. Results of the
microarray experiments are available in Gene Expression Omnibus (Accession Number
GSE15072).
Statistical analysis
Data are expressed as the mean ± standard deviation (SD). T-test and chi-square test were used
to assess differences in clinical and demographic features. A value of p< 0.05 was considered
to be statistically significant.
For microarray analysis, gene expression values for the 22,283 gene probe sets, scaled to the
target intensity of 2,500, were log transformed. Probe sets unexpressed in the entire microarray
cohort of patients were omitted. However, for our analysis we used only 14 gene probe sets
(corresponding to 5 genes) encoding for the biological elements included in the NLRP3 inflam-
masome according to NOD-like receptor signaling pathway in KEGG pathway analysis (http://
www.genome.jp/kegg/pathway.html). Principal component analysis (PCA) was performed
using Spotfire decision site 9.0 (www.spotfire.com). A p value cut-off of 0.005 was used to iden-
tify differentially expressed probe sets between the two groups.
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Results
Increased expression of genes encoding for NLRP3 inflammasome
components and pro-inflammatory cytokines in PBMC from CKD-HD
patients
RT-PCR demonstrated that mRNA levels of NLRP3, ASC, CASP-1 (inflammasome compo-
nents) and pro-inflammatory cytokines IL-1β and IL-18 were higher in PBMC isolated from
CKD-HD patients compared to NORM (Fig. 1).
P2X7 receptor (P2X7R), an ATP-gated cation channel that plays a key role in ATP-induced
inflammasome activation [44] was up-regulated in patients.
CARD 8, an inhibitor of the aforementioned inflammasome, resulted down-regulated in
CKD-HD versus controls (S2 Fig.).
These results reveal an enhanced inflammatory status in patients with severe renal failure
undergoing dialysis treatment.
Fig 1. NOD-like receptor 3 (NLRP3), apoptosis-associated speck-like protein containing a CARD domain (ASC), caspase-1 (CASP-1), IL-1β, IL-18
and P2XR7 gene expression by Real-Time PCR in PBMC from healthy subjects (NORM) and hemodialyzed chronic kidney disease patients
(CKD-HD). Histograms represent the mean ± SD of (A) NLRP3, (B) ASC, (C) CASP-1, (D) IL-18, (E) IL-1β and (F) P2XR7mRNA levels determined by Real-
Time PCR in PBMC isolated from 15 NORM and 15 CKD-HD patients. For all genes, expression levels resulted significantly higher in CKD-HD compared to
NORM (*p<0.05, **p<0.01).
doi:10.1371/journal.pone.0122272.g001
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Increment of mitochondrial ROS level in CKD-HD compared to controls
To measure the mitochondrial ROS production in PBMC of CKD-HD patients, we used the
MitoSOX Red, a fluorogenic dye for selective detection of superoxide in mitochondria of
live cells.
CKD-HD patients showed a significant higher levels of mitochondrial ROS compared to
NORM (Fig. 2).
This result was in line with our previous findings demonstrating a CKD-related mitochon-
drial dysfunction [45] and it suggests a possible link between this organelle and
inflammasome activation.
Colocalization of NLRP3, ASC and mitochondria in PBMC from CKD-HD
patients
ROS are short-lived molecules and they can act as a signaling messenger only for a short dis-
tance [46]. Thus, to be effective NLRP3 should be localized in close proximity to mitochondria
Fig 2. Mitochondrial ROS production by FACS in PBMC from healthy subjects (NORM) and hemodialyzed chronic kidney disease patients
(CKD-HD). Freshly isolated PBMC from 10 NORM and 10 CKD were incubated with 5 μMMitosox RED for 10 min at 37°. After centrifugation at 4°C the cells
were analyzed for Mitosox signal in a flow cytometer. (A and B) Representative FACS image of PBMC from one NORM and one CKD-HD patient,
respectively. (C) Histogram indicates median value ± SD of Mitosox positive cells in CKD-HD and NORM. CKD-HD patients showed higher number of
positive cells compared to NORM (*p<0.05).
doi:10.1371/journal.pone.0122272.g002
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allowing an efficient sensing of the ROS produced by this organelle. To demonstrate the above
mentioned co-localization and to evaluate the activation of NLRP3 inflammasome in
CKD-HD patients, we performed confocal microscopy experiments using MitoTracker Deep
Red FM, a far red-fluorescent dye that stains mitochondria in live cells. Interestingly, NLRP3
protein co-localizes with ASC and mitochondria in PBMC from CKD-HD patients whereas it
remains in cytoplasmic granular structure in PBMC from NORM (Fig. 3).
These results show the activation of NLRP3 inflammasome in PBMC from CKD-HD pa-
tients with a possible involvement of mitochondria.
Caspase-1 activation and pro-inflammatory cytokines maturation in
PBMC from CKD-HD patients
Since the NLRP3 inflammasome once activated causes the proteolytic cleavage of caspase-1
and the subsequent maturation of pro-inflammatory cytokines [36], we decided to measure the
protein level of activated (cleaved) caspase-1 and mature IL1β and IL-18 in 10 CKD-HD pa-
tients and 10 NORM from the training-group.
As predictable, the protein levels of caspase and both cytokines were higher in CKD-HD pa-
tients compared to NORM (p<0.01) (Fig. 4).
Inhibitory effects of mitoTEMPO on caspase-1 activation and maturation
of IL-1β and IL-18 induced by LPS/ATP in PBMC from CKD-HD
To better assess the role of mitochondria in inflammasome activation, we measured the level of
CASP-1, IL-1β and IL-18 in PBMC from CKD-HD stimulated with LPS/ATP, Pathogen-
Fig 3. Colocalization of NLRP3, ASC andmitochondria in PBMC from hemodialyzed chronic kidney disease patients (CKD-HD). Freshly isolated
PBMC from 3 NORM and 3 CKD-HD were spotted on poly-L-lysine-coated slides and incubated with Mitotracker deep red (100 nM) for 30 min at 37°C. The
cells were washed and fixed with 4% PFA. After blocking with BSA 1%, the slides were incubated with anti-NLRP3 and anti-ASC antibodies. Then, the cells
were incubated with secondary antibodies and nuclei were stained with DAPI. The figure shows representative confocal image for NLRP3, ASC and
mitochondria in PBMC isolated from (upper) one CKD-HD patient and (lower) one NORM. NLRP3 protein co-localizes with ASC and mitochondria in PBMC
from CKD-HD patients, whereas it remains in cytoplasmic granular structure in PBMC from NORM.
doi:10.1371/journal.pone.0122272.g003
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associated molecular pattern (PAMP) and danger-associated molecular pattern (DAMP) sig-
nals able to activate NLRP3 inflammasome, in absence or presence of mitoTEMPO, an inhibi-
tor of mitochondrial ROS production.
As shown in Fig. 5, mitoTEMPO caused a reduction of caspase-1 activation and cytokines
maturation in CKD-HD.
These results confirmed the close association between inflammation and mitochondrial dys-
regulation in CKD-KD patients.
Microarray analysis confirmed a de-regulation of inflammasome genes
in CKD-HD patients compared to healthy subjects
Microarray analysis revealed that 5 up to 15 gene probe sets were able to discriminate
CKD-HD from NORM (cut-off of discrimination: p<0.005).
Significantly up-regulated genes in CKD-HD were CASP1, NLRP3 and NAIP5, while those
down-regulated were TXNIP and CARD8 (Fig. 6A).
Principal component analysis (PCA) using the expression levels of the aforementioned gene
probe sets was able to clearly discriminate in three dimensional space CKD-HD patients from
NORM (Fig. 6B).
Discussion
In this study, performed by using classical bio-molecular methodologies (RT-PCR, western
blot, FACS analysis, confocal microscopy) combined with an high-throughput technology (mi-
croarray), we found that the NLRP3 inflammasome was activated in immunocompetent pe-
ripheral cell lines isolated from uremic patients undergoing dialysis treatment.
Fig 4. Mature (cleaved) forms of Caspase-1, IL-1β and IL-18 in PBMC from healthy subjects (NORM) and hemodialyzed chronic kidney disease
patients (CKD-HD). Histograms represent the mean ± SD of (A) cleaved caspase-1, (B) IL-18 and (C) IL-1β protein levels, measured by western blotting, in
total cell lysates of PBMC isolated from 10 NORM and 10 CKD-HD. In the bottom, representative western blotting experiments. Protein levels were
significantly higher in CKD-HD patients compared to NORM (**p<0.01).
doi:10.1371/journal.pone.0122272.g004
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This result was in line with a previous study showing the inflammasome activation in kid-
ney tissue of mice with renal impairment followed to unilateral ureteral obstruction. Compared
with wild-type, Nlrp3-/- mice had less tubular injury, inflammation and fibrosis associated with
a reduction in caspase-1 activation and maturation of IL-1β and IL-18 [47].
Additionally in vitro studies have shown that elevated levels of IL-1β and IL-18, produced
during CKD, were able to promote renal tubulointerstitial fibrosis [48,49]. In particular, stimu-
lation of primary cultures of human renal fibroblast with IL-1β for 24 h caused, collagen type 1
production and secretion of fibronectin and transforming growth factor-β (TGF-β).
Similarly, tubular proximal epithelial cells stimulated with IL-18 showed increase alpha-
smooth muscle actin (α-SMA) expression, type I collagen and fibronectin production in dos-
age- and/or time-dependent manners.
Several papers, then, indicate that danger-associated molecular patterns (DAMPs) such as
extracellular ATP, ROS, extracellular matrix components, are capable to activate NLRP3
inflammasome in several renal diseases [39,50–54].
More recently, Zhuang et al demonstrated a pathogenic role of NLRP3 inflammasome/cas-
pase-1/mitochondria axis in mediating albumin-induced renal tubular injury [55]. Likewise,
Fig 5. Inhibitory effects of mitoTEMPO on caspase-1 activation andmaturation of IL-1β and IL-18 induced by LPS/ATP in PBMC from
hemodialyzed chronic kidney disease patients (CKD-HD). PBMC from 3 CKD-HD were primed with LPS (10 ng/ml) for 4 h in presence or absence of
MitoTEMPO (100 μM) and stimulated with ATP (1 mM) for 15 minutes. Histograms represent the mean ± SD of (A) cleaved caspase-1, (B) IL-1β and (C) IL-
18 proteins level in total cell lysates. The intensity of each protein was quantified and normalized to the signal intensity of the corresponding procaspase-1,
pro-IL-1β, or pro-IL-18 band present on the samemembrane. In the upper part, representative western blotting experiments for (A) CASP-1, (B) IL-1β and (C)
IL-18. In all experiments, MitoTEMPO caused a reduction on caspase-1 activation and maturation of IL-1β and IL-18 induced by LPS/ATP. *p<0.05,
**p<0.01 vs CTR; #p<0.05, ##p<0.01 vs LPS/ATP.
doi:10.1371/journal.pone.0122272.g005
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mitochondrial ROS and NLRP3 inflammasome activation aggravate diabetic nephropathy in
non myeloid-derived cells [56].
Additionally, in the current study, we found elevated production of mitochondrial ROS in
PBMC from CKD-HD patients confirming mitochondrial impairment we previously reported
[45]. In fact, using an innovative high-throughput technology, we discovered that several bio-
logical elements involved in the oxidative phosphorylation system (OXPHOS) and two key
constituents of the mitochondrial complex IV (COXI and COXIV) were deregulated in CKD
and HD patients compared to the healthy controls.
Fig 6. NLRP3 inflammasome genes differentially expressed in PBMC from healthy subjects (NORM)
versus hemodialyzed chronic kidney disease patients (CKD-HD) and principal component analysis
(PCA) discriminating patients from controls. (A) Histogram shows the normalized level of expression of
CASP1, NLRP3, NAIP5, TXNIP andCARD8 in CKD-HD and NORM. (B) PCA, built using the expression level
of the above-mentioned genes, demonstrates the degree of discrimination in three dimensional space of the
study groups. Blue dots indicate NORM and red dots CKD-HD patients.
doi:10.1371/journal.pone.0122272.g006
NLRP3 Inflammasome and CKD Patients
PLOS ONE | DOI:10.1371/journal.pone.0122272 March 23, 2015 11 / 16
Furthermore, complex IV activity, the terminal enzyme of the mitochondrial respiratory
chain catalyzing the electron transfer from reduced cytochrome c to oxygen [57], resulted sig-
nificantly lower in CKD-HD patients compared to healthy controls demonstrating a reduced
activity of OXPHOS in this population.
It is conceivable that ROS produced by damaged organelles, in our patients’ population,
could be one of the abovementioned signal 1 in NLRP3 inflammasome activation.
In fact, in this paper, colocalization of NLRP3/ASC/mitochondria together with the inhibi-
tory effect of mitoTEMPO (an inhibitor of mitochondrial ROS production) on CASP-1 matu-
ration and cytokines activation in PBMC from CKD-HD patients confirm the involvement of
this organelle.
This effect has been previously demonstrated through two biological/biochemical mecha-
nisms that cause generation of ROS: inhibition of complex I or III of the mitochondrial respira-
tory chain and inhibition of mitophagy/autophagy resulting in the prolonged presence of
damaged mitochondria [58–60].
Contrarily, Schreiber et al [61] have recently found ROS to be potent suppressors of inflam-
masome. In particular, Phox-generated ROS downregulate caspase 1, thereby keeping the
inflammasome in check and limiting antineutrophil cytoplasmic antibody (ANCA)-
induced inflammation.
Notably, although extremely interesting, these unexpected data have been obtained, by a
fashionable set of experiments, in a mouse model of ANCA-associated crescentic glomerulone-
phritis. However, because of the extreme complexity of the disease and the lack of etiopathoge-
netic information, no patients with this disease have been included in our study.
Moreover, microarray and principal component analysis, showed that 5 up to 15 gene probe
sets were able to discriminate CKD-HD from NORM.
Significantly up-regulated genes in CKD-HD were CASP1, NLRP3 and NAIP5, while those
down-regulated were TXNIP and CARD8 (Fig. 6A).
Interestingly, caspase recruitment domain–containing protein (CARD) 8 (also known as
tumor CARD-containing antagonist of caspase nine-TUCAN), resulted down-regulated. This
protein interacts physically with caspase-1 and negatively regulates caspase-1-dependent IL-1β
expression [62,63]. A down-regulation of this protein has been reported in a model of human
pancreatic islets isolated for transplantation exposed to oxidative stress. Authors suggested that
an increased production of ROS and subsequent oxidative stress, through CARD8 down-
regulation, represents a possible mechanism by which high concentrations of glucose could kill
beta cells [64].
However, limitations of this part of the study is the unusual bioinformatic analysis (because
the low number of patients we did not perform false discovery rate evaluation) and the unbal-
ance between patients and healthy subjects.
All together these data showed, for the first time, that NLRP3 inflammasome was activated
in uremic patients undergoing dialysis treatment and they suggested that this unphysiological
condition could be possibly induced by mitochondrial dysfunction.
Finally, NLRP3 inflammasome pathway could turn to be a valuable therapeutic target to
minimize or avoid severe clinical complications in chronic kidney disease patients with ad-
vanced renal impairment.
Conclusions
In conclusion, the present study reveals, for the first time, that damaged mitochondria of ure-
mic patients through an elevated production of ROS could be able to activate NLRP3
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inflammasome representing a new deregulated biological machinery and a novel therapeutic
target in CKD-HD patients.
Supporting Information
S1 Fig. Control for nonspecific staining (NLRP3 and ASC primary antibodies).
(TIF)
S2 Fig. Caspase recruitment domain–containing protein (CARD) 8 gene expression by
Real-Time PCR in PBMC from healthy subjects (NORM) and hemodialyzed chronic kid-
ney disease patients (CKD-HD).Histogram represents the mean ± SD of CARD8 mRNA
level determined by Real-Time PCR in PBMC isolated from 15 NORM and 15 CKD-HD pa-
tients. Expression levels resulted significantly higher in CKD-HD compared to NORM.
(TIF)
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